ABSTRACT
We assessed cancer concordance, cancer incidence in the healthy twin of cancer probands, and cancer risk in relation to birth order in pediatric and adolescent/young adult twins via a population-based study in California from 1982-2022. Twin subjects born in California between 1982-2017 who were diagnosed with leukemia from 0-39 years of age were identified through linked birth and California Cancer Registry (1988-2022) data. Two concordant-twin leukemias cases were identified across 255 total twin pairs with leukemia for an overall rate of leukemia concordance of 0.9%. One concordant twin pair was identified among 199 pairs with lymphoid leukemia (0.5%) and one within 34 pairs with acute myeloid leukemia (2.9%). A significant association was identified between twin plurality birth order and development of leukemia (OR 1.18, 95% CI 1-1.39, P=0.049), an effect which was strongest in lymphoid leukemias (2.21, 1.44-3.39, P=1.65e-4). Assessment of DNA methylation markers associated with birth order showed significantly reduced methylation in first-born twin cases compared to second-born (P=8.53e-12) in a subset of 41 twins discordant for lymphoid leukemia. Overall cancer concordance in twins was comparable to the lower range of previous estimates from different world regions. Concordance in lymphoid leukemias was quite lower than expected, indicating concordant leukemia is rarer than previously appreciated. We identified a strong association between twin plurality birth order and development of pediatric cancer. While the underlying cause of this finding is uncertain, we identified significant differences in DNA methylation at previously described sites associated with birth order, suggesting a similar biological mechanism.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology, and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement U58DP003862-01 awarded to the California Department of Public Health. The ideas and opinions expressed herein are those of the author(s), and no endorsement by the California Department of Public Health, the National Cancer Institute, or the Centers for Disease Control and Prevention or their contractors and subcontractors is intended or should be inferred.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Institutional Review Boards at the California Health and Human Services Agency Committee for the Protection of Human Subjects and the University of Southern California.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from California Department of Public Health. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors with the permission of the California Department of Public Health. All available processed data are contained in the manuscript and its supplementary materials.